Search Results 341-350 of 18228 for Immunode

1. A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis (Cielo) - Mayo Clinic

   * Congenital or acquired immunodeficiency, including HIV infection * Active or presence of recurrent bacterial, viral, fungal, mycobacterial infection, or ...

2. A Study of Whole Blood-based Blood Biomarker (i.e., cytokine) that May Predict Status and Severity of Diseases - Mayo Clinic

   Those who have a history of primary immunodeficiency disorders identified by the International Union of Immunological Societies (2013); Those with medical ...

3. A Study to Evaluate the Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer - Mayo Clinic

   Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies). Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g. ...

4. Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma - Mayo Clinic

   Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any ... Known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).

5. Study of Pembrolizumab Combined with Decitabine and Pralatrexate in Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma - Mayo Clinic

   Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies). Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g. ...

6. Asthma Ascertainment and Characterization through Electronic Health Records - Mayo Clinic

   ... immunodeficiency disorder (or conditions identified by the International Union of Immunological Societies at index date of AIICs), primary ciliary ...

7. Publications - Amir A. Sadighi Akha, M.D., Ph.D. - Mayo Clinic

   A Toolkit and Framework for Optimal Laboratory Evaluation of Individuals with Suspected Primary Immunodeficiency. J Allergy Clin Immunol Pract. 2021 Sep; 9 ...

8. A Study to Evaluate the Safety and Tolerability of DCC-2618 in Patients with Advanced Malignancies - Mayo Clinic

   Known human immunodeficiency virus or hepatitis C infection only if the patient is taking medications that are described in Section 5.8.2.2, active ...

9. Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer - Mayo Clinic

   Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this ...

10. Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors - Mayo Clinic

    ... immunodeficiency virus (HIV) infection, or active Hepatitis B or Hepatitis C]. Use of other investigational agents within 30 days or 5 half-lives prior to ...